TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Demichelis, F.; Fall, K.; Perner, S.; Andrén, O.; Schmidt, F.; Setlur, S. R.; Hoshida, Y.; Mosquera, J.; Pawitan, Y.; Lee, C.; Adami, H.; Mucci, L. A.; Kantoff, P. W.; Andersson, S.; Chinnaiyan, A. M.; Johansson, J.; Rubin, M. A.

doi:10.1038/sj.onc.1210237

CINECA IRIS Institutional Research Information System

IRIS è l'Anagrafe della ricerca dell'Università degli Studi di Trento, e ha lo scopo di raccogliere, documentare, diffondere e conservare le informazioni relative alla produzione scientifica degli autori afferenti all'Università degli Studi di Trento.

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Scheda prodotto non validato

I dati visualizzati non sono stati ancora sottoposti a validazione formale da parte dello Staff di IRIS, ma sono stati ugualmente trasmessi al Sito Docente Cineca (Loginmiur).

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11572/88989

Titolo:	TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Autori Unitn:	Demichelis, Francesca
Anno di pubblicazione:	2007
Titolo del periodico:	ONCOGENE
Abstract:	The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.
Handle:	http://hdl.handle.net/11572/88989
Appare nelle tipologie:	03.1 Articolo su rivista (Journal article)

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione